Bio Essence Corp. reported significant financial improvements in its fiscal year ending December 31, 2025, with total revenues reaching $1.9 million, a substantial increase from $323,940 in the previous year. The company attributed this growth primarily to a 570.68% rise in revenue from Original Equipment Manufacturing (OEM) services, which accounted for $1.9 million of total revenues, while product sales dropped to zero from $37,415 in 2024. The gross profit for the year was $1.4 million, compared to $217,077 in 2024, reflecting a gross profit margin of 75.28%.
The company underwent significant operational changes during the fiscal year, including the sale of its subsidiaries, Bio Essence Pharmaceutical, Inc. and Bio Essence Herbal Essentials Inc., for $300,000 and $400,000, respectively. Following these divestitures, Bio Essence has shifted its operational focus to directly managing its sales of health supplements and providing OEM services, outsourcing manufacturing processes. The company currently has four full-time employees, a reduction in operational scale following the dissolution of its subsidiaries.
In terms of financial health, Bio Essence reported a net income of $896,197 for 2025, a stark contrast to the net loss of $1.6 million recorded in 2024. This turnaround was attributed to increased revenues and a reduction in general and administrative expenses, which fell by 26.42% to $497,809. The company also reported a working capital deficit of $2 million and a current ratio of 0.17:1, indicating potential liquidity challenges ahead.
Looking forward, Bio Essence plans to enhance its sales force and marketing efforts to drive revenue growth. The company is also exploring options for additional financing, including potential public or private offerings, to support its operations. However, management has acknowledged that the ability to continue as a going concern is contingent upon successfully implementing its business strategy and generating sufficient revenue. The company has indicated a need for approximately $1.2 million in cash to sustain operations over the next 12 months.
In addition to its financial performance, Bio Essence is currently facing legal challenges, including a lawsuit filed by Stason Industrial Corporation, which alleges breach of contract and seeks damages of approximately $1.5 million. The company has denied the allegations and is preparing to defend its position. As it navigates these challenges, Bio Essence remains focused on its strategic objectives and operational adjustments to stabilize and grow its business in the competitive health supplement market.
About Bio Essence Corp
Bio Essence Corp. is a California-based company specializing in herbal health, diet, and nutritional supplements. It offers traditional Chinese medicine products, dietary supplements, and OEM manufacturing services, primarily serving health-conscious consumers and businesses. The company operates by outsourcing manufacturing while focusing on product development, sales, and private label services. Its core value lies in combining herbal and nutritional expertise to provide natural health solutions in the wellness market.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.